Comparative efficacy of fingolimod vs natalizumab

Overview of attention for article published in Neurology, January 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 3 news outlets
blogs: 3 blogs

twitter: 10 X users

Citations

dimensions_citation: 71 Dimensions

Readers on

mendeley: 51 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Study Compares Efficacy of Two MS Treatments in Reducing Relapses

MPR, 04 Feb 2016

Share this article: The findings provide Class IV evidence for superiority A retrospective analysis found that natalizumab is…

Natalizumab shows relapse prevention benefits over fingolimod in MS

The Medical News, 04 Feb 2016

By Lucy Piper, Senior medwireNews Reporter Natalizumab may be superior to fingolimod for preventing relapses during the first…

Natalizumab shows relapse prevention benefits over fingolimod in MS

medwireNews, 03 Feb 2016

medwireNews : Natalizumab may be superior to fingolimod for preventing relapses during the first year of treatment in patients…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.